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Abstract
Introduction: Data are sparse as to whether obesity influences the risk of death in critically ill patients with septic
shock. We sought to examine the possible impact of obesity, as assessed by body mass index (BMI), on hospital
mortality in septic shock patients.
Methods: We performed a nested cohort study within a retrospective database of patients with septic shock
conducted in 28 medical centers in Canada, United States and Saudi Arabia between 1996 and 2008. Patients were
classified according to the World Health Organization criteria for BMI. Multivariate logistic regression analysis was
performed to evaluate the association between obesity and hospital mortality.
Results: Of the 8,670 patients with septic shock, 2,882 (33.2%) had height and weight data recorded at ICU
admission and constituted the study group. Obese patients were more likely to have skin and soft tissue infections
and less likely to have pneumonia with predominantly Gram-positive microorganisms. Crystalloid and colloid
resuscitation fluids in the first six hours were given at significantly lower volumes per kg in the obese and very
obese patients compared to underweight and normal weight patients (for crystalloids: 55.0 ± 40.1 ml/kg for
underweight, 43.2 ± 33.4 for normal BMI, 37.1 ± 30.8 for obese and 27.7 ± 22.0 for very obese). Antimicrobial doses
per kg were also different among BMI groups. Crude analysis showed that obese and very obese patients had
lower hospital mortality compared to normal weight patients (odds ratio (OR) 0.80, 95% confidence interval (CI)
0.66 to 0.97 for obese and OR 0.61, 95% CI 0.44 to 0.85 for very obese patients). After adjusting for baseline
characteristics and sepsis interventions, the association became non-significant (OR 0.80, 95% CI 0.62 to 1.02 for
obese and OR 0.69, 95% CI 0.45 to 1.04 for very obese).
Conclusions: The obesity paradox (lower mortality in the obese) documented in other populations is also
observed in septic shock. This may be related in part to differences in patient characteristics. However, the true
paradox may lie in the variations in the sepsis interventions, such as the administration of resuscitation fluids and
antimicrobial therapy. Considering the obesity epidemic and its impact on critical care, further studies are
warranted to examine whether a weight-based approach to common therapeutic interventions in septic shock
influences outcome.
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Introduction
Obesity is a fast growing epidemic worldwide and is clo-
sely associated with morbid conditions including dia-
betes, cardiovascular and respiratory diseases as well as
cancer [1]. Approximately 65% of the United States
population is overweight and 30% are obese. Obesity is
increasingly a major health hazard in many developed
and developing nations as well [2-4]. As a result, the
proportion of obese patients admitted to hospitals is
steadily increasing with an estimated cost that exceeds
5% of the national health expenditure in the US [2,3].
Therefore, obesity became the target for national-level
endeavors as evidenced by the most recent release of
the Institute of Medicine recommendations to ‘Solve the
Weight of the Nation’ [5].
The prevalence of obese patients admitted to ICUs is
also rising rapidly and poses complex challenges [6,7].
However, intriguingly, despite the increased morbidity
and the difficulty of administering standard care, data
on outcome, although conflicting, are showing predomi-
nantly either equal or lower mortality in obese than in
normal weight critically ill patients, while only a few
reported higher mortality [8,9]. A comparable phenom-
enon was also observed in obese patients with heart fail-
ure and is referred to as the ‘obesity paradox’ [10].
Although an explanation of this paradox is not immedi-
ately clear, most of the studies have included either a
heterogeneous population of obese critically ill patients
or have failed to adjust for major confounding factors,
such as sepsis interventions [11,12]. The influence of
obesity on specific ICU populations, such as patients
with sepsis, has been the subject of much speculation
but very few clinical data exist on this topic.
Sepsis is a major cause of morbidity and mortality
worldwide and a leading admission diagnosis to ICUs
[13] with substantial cost and considerable long-term
health-related consequences [14-16]. Data on the impact
of obesity on septic shock are primarily based on experi-
mental and small clinical studies [17,18].
Therefore, we sought to examine the association of
obesity, assessed by body mass index (BMI), and hospi-
tal mortality in patients admitted with septic shock. We
further assessed the differences in clinical and microbio-
logic features as well as septic shock-related interven-
tions in association with obesity.
Materials and methods
Subjects and setting
This was a retrospective cohort study from a large data-
base of patients admitted with septic shock to the ICUs in
28 medical centers in Canada, United States, and Saudi
Arabia by the Cooperative Antimicrobial Therapy of Sep-
tic Shock (CATSS) Database Research Group between
1996 and 2008. The study protocol was approved by the
Instititutional Review Board of the University of Manitoba,
Winnipeg, Canada; the University of Toronto, Toronto,
Canada; McGill University, Montreal, Canada; the Univer-
sity of British Columbia, Vancouver, Canada; Rush Univer-
sity, Chicago, IL, USA; Brandon Hospital, Brandon,
Canada; St. Agnes Hospital, Baltimore, MD, USA; Harper
Hospital, Detroit, MI, USA; Northern Medical School,
Laurentian University, Sudbury, Canada; the University of
Calgary, Calgary, Canada; the University of Wisconsin,
Madison, WI, USA; Cooper Hospital/University Medical
Center, Camden, NJ, USA; Vancouver Island Regional
Health Authority, Victoria, Canada; Hospital Maisso-
neuve-Rosemont, Montreal, Canada; and King Saud Bin
Abdulaziz University for Health Sciences, Riyadh, Saudi
Arabia. Informed consent was waived.
The original study included adult patients with septic
shock defined according to the 1992 American College
of Chest Physicians/Society of Critical Care Medicine
guidelines [19]. The details regarding the full definitions
used in the study have already been described [20,21].
Patients with weight and height documented in the
medical records on admission were included in this
study.
Definition of obesity
Obesity was defined using the World Health Organization
(WHO) criteria according to BMI (calculated as weight in
kilograms divided by the square of the height in meters
(kg/m2)) [22]. Patients were classified as underweight
(BMI < 18.50 kg/m2), normal weight (BMI = 18.50 to
24.99 kg/m2), overweight (BMI = 25.0 to 29.99 kg/m2),
obese (BMI = 30.0 to 39.99 kg/m2) or very obese (BMI >
40 kg/m2).
Clinical characteristics and sepsis interventions
At baseline the following data were collected: age, gender,
use of mechanical ventilation, Acute Physiology and
Chronic Health Evaluation (APACHE) II score [23],
admission physiologic data and comorbid conditions
(immunosuppressive disorders, liver failure, heart failure,
chronic obstructive pulmonary disease (COPD), chronic
renal failure and medication- and insulin-dependent dia-
betes, alcohol abuse, elective and emergency surgery),
laboratory data, organ failure indicators on admission [see
Additional file 1, Appendix A], source of infection (com-
munity versus nosocomial infection), the presence of bac-
teremia, site of infection and microbiological data. We
calculated creatinine clearance using the modification of
diet in renal disease (MDRD) [24] and Cockcroft-Gault
equations [25] [see Additional file 1, Appendix B]; the for-
mer was used in the multivariate analysis as it has been
shown to perform better than Cockcroft-Gault equation in
patients with extreme weights [26]. We calculated ideal
and adjusted body weights and dosing weights for
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antimicrobials as recommended [6,27] [see Additional
file 1, Appendix B].
We documented the following data regarding sepsis
interventions: the volume of crystalloids, colloids, and
blood products administered during the first six hours
of septic shock (in ml and in ml/kg of actual body
weight). We also recorded the selection and doses of
vasopressors, use of activated protein C and low-dose
steroids. The following data were collected about anti-
microbial therapy: appropriateness, delay in hours from
the onset of hypotension and the use of single versus
combination antimicrobial therapy. Detailed definitions
of these variables have already been described
[20,21,28]. We also documented the type and dose (total
and dose per kg of dosing body weight) of antimicro-
bials administered on the first day.
Outcomes
Hospital mortality was the primary outcome. Secondary
outcomes were ICU mortality and ICU and hospital
length of stay (LOS).
Statistical analysis
Continuous variables are reported as means with stan-
dard deviations (SD) and categorical variables as abso-
lute and relative frequencies. Analysis of variance
(ANOVA) and chi-square tests for comparison among
groups were used as appropriate.
To study the association between obesity and hospital
mortality, we carried out multivariate logistic regression
analyses with the normal weight group as reference. We
assessed the association of different BMI groups and mor-
tality in crude and multivariate models adjusting for covari-
ates that were selected based on clinical relevance or
statistical criteria (P value of 0.25 for inclusion and P value
of 0.05 for retaining in the model). We first adjusted to
baseline characteristics (model 1) including age, gender,
mechanical ventilation, APACHE II score, chronic co-mor-
bidities (immunosuppressive disorders, heart failure,
COPD, and medication- and insulin-dependent diabetes,
elective surgery), nosocomial versus community acquired
infection, bacteremia, Gram-negative organisms, fungal
organisms, anaerobes (with Gram-positive organisms used
as reference), pneumonia, urinary tract infection, primary
bloodstream infection, catheter-related bloodstream infec-
tion, skin and soft tissue infection, creatinine clearance as
calculated by MDRD and country. To adjust for the impact
of potential changes in practice over time, we divided the
study time period into four quartiles and we included the
study period in the multivariate model. In the second
model (model 2) we added the following variables related
to sepsis interventions: inappropriate antimicrobial therapy,
single versus combination antimicrobial therapy, delayed
antimicrobial therapy > 3 hours, vasopressor doses (dopa-
mine, norepinephrine, phenylephrine, epinephrine, and
dobutamine), the use of a pulmonary artery catheter, acti-
vated protein C and the use of low-dose steroids. Among
the variables included in the multivariate models, 3% of
patients had missing values for APACHE II score and 3.5%
of patients had missing data for MDRD, which were
replaced by the means. Results were reported as odds ratios
(ORs) with 95%CIs.
To study the association between BMI and the amount
of fluid and antimicrobial dosage, we carried out multi-
variate linear regression analyses. We reported P values
for the crude analysis and adjusted analysis for creatinine
clearance. For the association of fluids and BMI, we also
adjusted for pulmonary capillary wedge pressure in
patients with a pulmonary artery catheter. A P value of <
0.05 was considered significant. SAS (SAS Institute, Cary,
NC, USA) software was used for statistical analyses.
Results
Baseline characteristics
Of the 8,670 patients included during the study period,
2,882 (33.2%) had height and weight documented.
When compared to excluded patients who did not have
documented values of both weight and height in the
medical records, there were no differences in age (P =
0.07), APACHE II score (P = 0.10) and use of mechani-
cal ventilation (P = 0.29). However, excluded patients
were more likely to have comorbid conditions (P =
0.007) and had lower hospital mortality compared to the
included patients (P = 0.03).
Overall, 35.3% of the study population was in the normal
weight group, 6.8% were underweight, 28.3% overweight,
23.6% obese and 5.4% very obese. Table 1 shows their
baseline characteristics. Compared with the reference
group (normal weight), very obese and underweight
patients were younger. Obese and very obese patients
were less likely to have immunosuppressive disorders and
more likely to have heart failure and diabetes mellitus
compared to those with normal BMI. With increasing
BMI, admission heart rate, temperature and mean arterial
pressure were higher and respiratory rate was lower.
Creatinine was higher and platelet count lower with
increasing BMI with the corresponding organ failure indi-
cators following the same pattern (Table 1).
Microbiologic data and sites of infections
Obese and very obese patients were more likely to have
Gram-positive infections. Very obese patients were more
likely to have sepsis from skin and soft tissue infections
and less from pneumonia (Table 2). Table 3 shows the
sepsis interventions and Table 4 shows the fluid and
antibiotic dosage among the five groups of BMI.
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Age (years), mean (SD) 59.1 (19.2) 62.2 (16.8) 63.5 (15.9) 62.2 (14.6) 58.4 (13.0) < 0.001
Gender, female, number (%) 82 (41.8) 390 (38.2) 316 (38.7) 334 (49.1) 102 (60.0) < 0.001
Actual body weight (kg), mean (SD) 47.3 (7.1) 63.4 (10.2) 77.3 (10.1) 93.4 (14.7) 128.9 (28.1) < 0.001
Ideal body weight (kg), mean (SD) 61.7 (10.9) 62.9 (11.5) 62.4 (10.7) 60.4 (12.0) 58.3 (13.4) < 0.001
Dosing body weight (kg), mean (SD) 58.1 (9.7) 63.0 (10.9) 66.1 (10.4) 68.6 (12.3) 75.9 (15.8) < 0.001
Height (cms), mean (SD) 167.3 (10.6) 168.8 (11.1) 167.9 (10.1) 166.3 (11.5) 164.5 (13.3) < 0.001
BMI (kg/m2), mean (SD) 16.8 (1.3) 22.2 (1.8) 27.3 (1.4) 33.6 (2.7) 47.4 (7.4) < 0.001
Mechanical ventilation, number (%) 146 (74.5) 777 (76.2) 605 (74.1) 491 (72.2) 128 (75.3) 0.48
APACHE II, mean (SD) 25.5 (8.0) 25.7 (8.1) 25.6 (8.4) 25.4 (7.9) 24.4(7.3) 0.43
Admission physiologic data, mean (SD)
Heart rate (beats/minute) 120.9 (30.3) 119.2 (29.4) 116.7 (29.9) 119.1 (29.5) 112.2 (31.0) 0.02
Respiratory rate (beats/minute) 29.0 (8.8) 27.0 (10.2) 26.6 (10.4) 26.0 (10.0) 25.8 (9.1) 0.005
Temperature (°C) 37.2 (1.8) 37.5 (1.7) 37.7 (1.7) 37.8 (1.6) 37.8 (1.7) < 0.001
Mean arterial pressure (mmHg) 53.3 (13.3) 56.6 (16.5) 58.0 (19.0) 60.3 (20.1) 62.6 (22.2) < 0.001
Co-morbidities, number (%)
Immunosuppressive disorder 56 (28.6) 300 (29.4) 213 (26.1) 188 (27.7) 32 (18.8) 0.06
Liver failure 14 (7.1) 91 (8.9) 67 (8.2) 53 (7.8) 19 (11.2) 0.59
New York Heart Association class IV heart
failure
16 (8.2) 70 (6.9) 95 (11.6) 77 (11.3) 21 (12.4) 0.002
Severe COPD (requiring medication or oxygen) 22 (11.2) 102 (10.0) 88 (10.8) 83 (12.2) 32 (18.8) 0.02
Chronic renal failurea 35 (17.9) 155 (15.2) 126 (15.4) 100 (14.7) 34 (20.0) 0.43
Chronic renal failure-dialysis dependence 17 (8.7) 81 (7.9) 45 (5.5) 41 (6.0) 12 (7.1) 0.20
Diabetes mellitus (medication dependent) 10 (5.1) 127 (12.5) 141 (17.3) 159 (23.4) 45 (26.5) < 0.001
Diabetes mellitus (insulin-dependent) 11 (5.6) 76 (7.5) 82 (10.1) 80 (11.8) 35 (20.6) < 0.001
Alcohol abuse 29 (14.8) 162 (15.9) 107 (13.1) 76 (11.2) 15 (8.8) 0.02
Elective surgery 28 (14.3) 160 (15.7) 159 (19.5) 130 (19.1) 25 (14.7) 0.09
Emergency surgery/trauma 17 (8.7) 97 (9.5) 73 (9.0) 49 (7.2) 8 (4.7) 0.19
No co-morbidity 58 (29.6) 285 (27.9) 227 (27.8) 170 (25.0) 38 (22.4) 0.33
Any co-morbidity 138 (70.4) 735 (72.1) 589 (72.2) 510 (75.0) 132 (77.6)
Laboratory findings on day-1, mean (SD)
White blood count (×109/L) 16.1 (16.4) 16.1 (15.3) 16.5 (16.9) 17.9 (16.1) 16.0 (10.6) 0.20
Creatinine (μmol/L) 164.3 (148.2) 195.3 (160.6) 207.7 (167.9) 221.7 (165.2) 242.3 (201.8) < 0.001
Bicarbonate (mmol/L) 19.4 (6.7) 19.1 (6.4) 18.8 (6.4) 19.0 (6.7) 20.1 (6.1) 0.32
Bilirubin (μmol/L) 33.2 (54.4) 41.5 (76.3) 44.1 (92.5) 41.5 (68.1) 31.1 (76.0) 0.29
Platelets (×109/L) 206.9 (140.5) 198.4 (156.6) 185.6 (133.3) 210.3 (140.6) 223.5 (132.2) 0.004
International normalized ratio 1.8 (1.2) 1.7 (1.1) 1.8 (1.1) 1.8 (1.4) 1.7 (1.3) 0.78
Creatinine clearance (mL/minute), mean (SD)
MDRDb equation 85.9 (148.2) 56.5 (49.3) 48.1 (40.6) 43.1 (36.0) 37.1 (27.6) < 0.001
Cockcroft-Gault equation 69.6 (98.6) 49.8 (41.3) 42.3 (34.3) 37.9 (29.9) 33.6 (22.7) < 0.001
Source of infection, number (%)
Community acquired infection 102 (52.0) 555 (54.4) 410 (50.3) 350 (51.5) 105 (61.8) 0.06
Nosocomial infection 94 (48.0) 465 (45.6) 406 (49.8) 330 (48.5) 65 (38.2)
Bacteremia, Number (%) 68 (34.7) 361 (35.4) 289 (35.4) 266 (39.1) 48 (28.2) 0.10
Organ failures on day-1, number (%)
Cardiovascular 196 (100) 1020 (100) 816 (100) 680 (100) 170 (100) *
Renal 80 (40.8) 550 (53.9) 501 (61.4) 447 (65.7) 112 (65.9) < 0.001
Respiratory 146 (74.5) 777 (76.2) 605 (74.1) 491 (72.2) 128 (75.3) 0.48
Hematologic 56 (28.6) 261 (25.6) 241 (29.5) 163 (24.0) 29 (17.1) 0.006
Metabolic 110 (56.1) 551 (54.0) 441 (54.0) 367 (54.0) 91 (53.5) 1.00
Central nervous system 47 (24.0) 289 (28.3) 210 (25.7) 168 (24.7) 45 (26.5) 0.44
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Table 1 Baseline characteristics among different groups of BMI (Continued)
Hepatic 32 (16.3) 195 (19.1) 157 (19.2) 144 (21.2) 31 (18.2) 0.60
Coagulation 89 (45.4) 454 (44.5) 350 (42.9) 284 (41.8) 69 (40.6) 0.70
Country, number (%)
Canada 147 (75.0) 813 (79.7) 655 (80.3) 548 (80.6) 130 (76.5) 0.15
USA 28 (14.3) 101 (9.9) 90 (11.0) 75 (11.0) 28 (16.5)
Saudi Arabia 21 (10.7) 106 (10.4) 71 (8.7) 57 (8.4) 12 (7.1)
Period, number (%)
≤ 1997 57 (29.1) 301 (29.5) 218 (26.7) 191 (28.1) 32 (18.8) 0.18
1998 to 2000 72 (36.7) 378 (37.1) 292 (35.8) 235 (34.6) 67 (39.4)
2001 to 2002 57 (29.1) 296 (29.0) 265 (32.5) 207 (30.4) 62 (36.5)
≥ 2003 10 (5.1) 45 (4.4) 41 (5.0) 47 (6.9) 9 (5.3)
APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index;aSerum creatinine > 1.5 upper limit of normal,
aSerum creatinine > 1.5 upper limit of normal = Chronic renal failure
bMDRD: Modification of diet in renal disease
Table 2 Microbiologic and sites of infection among different groups of BMI



















Total culture negative 49 (25.0) 270 (26.5) 242 (29.7) 204 (30.0) 53 (31.2) 0.28
Total culture positive 147 (75.0) 750 (73.5) 574 (70.3) 476 (70.0) 117 (68.8)
Gram-negative organisms 72 (36.7) 384 (37.7) 281 (34.4) 230 (33.8) 45 (26.5) 0.05
Escherichia coli 23 (11.7) 163 (16.0) 115 (14.1) 97 (14.3) 19 (1.2) 0.32
Klebsiella 16 (8.2) 62 (6.1) 41 (5.0) 36 (5.3) 7 (4.1) 0.38
Pseudomonas aeruginosa 13 (6.6) 68 (6.7) 48 (5.9) 28 (4.1) 8 (4.7) 0.23
Enterobacter species 5 (2.6) 27 (2.7) 21 (2.6) 25 (3.7) 1 (0.6) 0.25
Haemophilus influenzae 6 (3.1) 12 (1.2) 10 (1.2) 8 (1.2) 3 (1.8) 0.29
Acinetobacter species 4 (2.0) 10 (1.0) 6 (0.8) 11 (1.6) 2 (1.2) 0.38
Other Gram-negative bacilli 5 (2.6) 42 (4.1) 40 (4.9) 25 (3.7) 5 (2.9) 0.49
Gram-positive organisms 41 (20.9) 247 (24.2) 183 (22.4) 168 (24.7) 60 (35.3) 0.007
Staphylococcus aureus 19 (9.7) 110 (10.8) 81 (9.9) 71 (10.4) 22 (12.9) 0.81
Streptococcus pneumonia 9 (4.6) 60 (5.9) 37 (4.5) 37 (5.4) 8 (4.7) 0.74
Streptococci faecalis 4 (2.0) 19 (1.9) 17 (2.1) 17 (2.5) 6 (3.5) 0.68
Streptococcus faecium 2 (1.0) 11 (1.1) 8 (1.0) 4 (0.6) 3 (1.8) 0.69
Group A streptococcus species 2 (1.0) 18 (1.8) 17 (2.1) 14 (2.1) 10 (5.9) 0.01
Other b-hemolytic streptococci 3 (1.5) 12 (1.2) 10 (1.2) 13 (1.9) 8 (4.7) 0.01
Other Gram-positive bacilli 2 (1.0) 17 (1.7) 13 (1.6) 12 (1.8) 3 (1.8) 0.97
Fungi/Yeast 20 (10.2) 77 (7.6) 84 (10.3) 62 (9.1) 8 (4.7) 0.08
Candida albicans 11 (5.6) 44 (4.3) 50 (6.1) 37 (5.4) 7 (4.1) 0.46
Other candida/yeast 9 (4.6) 33 (3.2) 34 (4.2) 25 (3.7) 1 (0.6) 0.18
Anaerobes 10 (5.1) 26 (2.6) 17 (2.1) 14 (2.1) 4 (2.4) 0.15
Other organisms 4 (2.0) 16 (1.6) 9 (1.1) 2 (0.3) 0 0.04
Site of infection
Lung 95 (48.5) 445 (43.6) 301 (36.9) 226 (33.2) 53 (31.2) <
0.001
Pneumonia 91 (46.4) 435 (42.7) 296 (36.3) 223 (32.8) 51 (30.0) 0.45
Empyema 4 (2.0) 10 (1.0) 5 (0.6) 3 (0.4) 2 (1.2) 0.22
Intraabdominal 53 (27.0) 299 (29.3) 268 (32.8) 228 (33.5) 53 (31.2) 0.20
Intraabdominal abscess 5 (2.6) 23 (2.3) 23 (2.8) 28 (4.1) 8 (4.7) 0.15
Ascending Cholangitis 2 (1.0) 23 (2.3) 14 (1.7) 13 (1.9) 0 0.28
Cholecystitis 1 (0.5) 9 (0.9) 14 (1.7) 12 (1.8) 1 (0.6) 0.26
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Table 2 Microbiologic and sites of infection among different groups of BMI (Continued)
Ischemic bowel/bowel infarction 7 (3.6) 48 (4.7) 51 (6.3) 35 (5.2) 5 (2.9) 0.27
Viscous bowel perforation 21 (10.7) 104 (10.2) 104 (12.8) 66 (9.7) 20 (11.8) 0.34
Spontaneous bacterial peritonitis 3 (1.5) 31 (3.0) 14 (1.7) 17 (2.5) 1 (0.6) 0.16
Clostridium difficile enterocolitis/toxic megacolon 7 (3.6) 25 (2.5) 18 (2.2) 12 (1.8) 2 (1.2) 0.49
Infected pancreatic necrosis 0 4 (0.4) 11 (1.4) 16 (2.4) 3 (1.8) 0.002
Others 7 (3.6) 32 (3.1) 19 (2.3) 29 (4.3) 13 (7.7) 0.009
Skin and soft tissue 14 (7.1) 69 (6.8) 72 (8.8) 79 (11.6) 37 (21.8) <
0.001
Cellulitis 2 (1.0) 7 (0.7) 11 (1.4) 19 (2.8) 12 (7.1) <
0.001
Necrotizing soft tissue infections 5 (2.6) 20 (2.0) 16 (2.0) 23 (3.4) 12 (7.1) 0.001
Others 7 (3.6) 42 (4.1) 45 (5.5) 37 (5.4) 13 (7.7) 0.22
Genitourinary 17 (8.7) 92 (9.0) 80 (9.8) 70 (10.3) 18 (10.6) 0.88
Intravascular catheter infection 8 (4.1) 38 (3.7) 29 (3.6) 36 (5.3) 6 (3.5) 0.46
Primary bloodstream infection (bacteremia without
identifiable source)
8 (4.1) 49 (4.8) 44 (5.4) 37 (5.4) 7 (4.1) 0.87
Systemically disseminated infection (including yeast and
tuberculosis)
6 (3.1) 29 (2.8) 26 (3.2) 18 (2.7) 5 (2.9) 0.98
Septic arthritis 0 5 (0.5) 7 (0.9) 7 (1.0) 6 (3.5) 0.002
BMI, body mass index.



















Vasopressors used, Number (%)
Dopamine 117 (59.7) 594 (58.2) 465 (57.0) 408 (60.0) 91 (53.5) 0.54
Norepinephrine 122 (62.2) 566 (55.5) 480 (58.8) 362 (53.2) 86 (50.6) 0.04
Phenylephrine 58 (29.6) 336 (32.9) 255 (31.3) 219 (32.2) 48 (28.2) 0.70
Epinephrine 12 (6.1) 45 (4.4) 41 (5.0) 31 (4.6) 15 (8.8) 0.15
Dobutamine 16 (8.2) 98 (9.6) 84 (10.3) 75 (11.0) 18 (10.6) 0.77
Vasopressor dose - at six hours, mean (SD)
Dopamine (μcg/kg/minute) 7.7 (7.3) 6.7 (4.9) 6.5 (4.7) 6.4 (4.3) 6.2 (5.1) 0.22
Norepinephrine (μcg/kg/minute) 0.39 (0.41) 0.37 (0.60) 0.33 (0.43) 0.30 (0.47) 0.18 (0.18) 0.05
Phenylephrine (μcg/kg/minute) 3.4 (4.1) 2.2 (2.1) 2.1 (2.3) 2.0 (2.4) 1.2 (1.4) 0.003
Epinephrine (μcg/kg/minute) 0.85 (0.61) 0.30 (0.26) 0.33 (0.73) 0.18 (0.12) 0.21 (0.18) 0.04
Dobutamine (μcg/kg/minute) 5.1 (1.7) 4.4 (2.5) 4.7 (2.9) 4.0 (2.8) 4.4 (2.5) 0.82
Sepsis specific therapy
Activated protein C, number (%) 9 (4.6) 36 (3.5) 29 (3.6) 42 (6.2) 13 (7.7) 0.01
Low-dose steroids, number (%) 73 (37.2) 305 (29.9) 256 (31.4) 222 (32.7) 46 (27.1) 0.19
Inappropriate antimicrobials therapy, number (%) 46 (23.5) 188 (18.4) 160 (19.6) 120 (17.7) 31 (18.2) 0.43
Single versus combined antimicrobial therapy,
number (%)
142 (72.5) 711 (69.7) 568 (69.6) 456 (67.1) 118 (69.4) 0.62
Delay in antimicrobial therapy, mean (SD) 17.8 (30.3) 13.9 (24.0) 15.1 (26.0) 12.6 (18.8) 16.7 (29.9) 0.12
Others
Pulmonary artery catheter, number (%) 91 (46.4) 513 (50.3) 428 (52.5) 386 (56.8) 89 (52.4) 0.04
Pulmonary capillary wedge pressure, (mmHG), mean
(SD)
15.0 (5.2) 16.5 (6.1) 17.6 (6.1) 18.6 (6.4) 20.5 (6.7) < 0.001
Cardiac output (L/minute), mean (SD) 6.4 (2.8) 7.1 (3.2) 7.6 (3.2) 7.7 (3.4) 8.7 (3.5) < 0.001
Cardiac index(L/minute/m2), mean (SD) 4.1 (1.7) 4.1 (1.7) 4.0 (1.6) 3.8 (1.5) 3.9 (1.5) 0.11
BMI, body mass index.
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Total (ml) 2,580.3 (1,874.9) 2,690.0 (2,050.2) 2,861.7 (2,445.1) 2,537.4 (2,032.0) 2,602.3 (1,919.1) 0.30 0.76 0.59
Dose per kg of actual body weight
(ml/kg)
55.0 (40.1) 43.2 (33.4) 37.1 (30.8) 27.7 (22.0) 21.4 (16.8) <
0.001
< 0.001 < 0.001










Total (ml) 656.8 (864.8) 509.8 (781.0) 593.5 (788.7) 705.5 (2,824.5) 538.9 (939.8) 0.44 0.79 0.31
Dose per kg of actual body weight
(ml/kg)
14.3 (19.3) 8.2 (12.7) 7.7 (10.2) 8.5 (44.2) 4.3 (7.2) 0.06 0.02 < 0.001
Packed red blood
cell
Number = 94 (3.3%) Number = 5 (2.6) Number = 29
(2.8)
Number = 31(3.8) Number = 24
(3.5)
Number = 5 (2.9)
Total (ml) 462.0 (180.7) 601.0 (630.3) 522.5 (243.2) 502.0 (250.0) 961.2 (781.5) 0.26 0.68 0.79
Dose per kg of actual body weight
(ml/kg)
9.6 (4.1) 9.7 (10.8) 6.8 (3.1) 5.4 (3.0) 7.3 (5.5) 0.18 0.02 0.53
Fresh frozen plasma Number 70 (2.4%) Number = 4 (2.0) Number = 22
(2.2)
Number = 21(2.6) Number = 18
(2.6)
Number = 5 (2.9)
Total (ml) 737.5 (715.7) 498.7 (224.4) 600.0 (336.9) 526.8 (333.1) 1,260.0 (1,34.9) 0.01 0.005 0.02
Dose per kg of actual body weight
(ml/kg)
18.9 (20.8) 8.2 (4.4) 7.8 (4.7) 5.8 (3.7) 10.4 (8.4) 0.01 0.77 0.62
Piperacillin/tazo-
bactam










Total dose (mg) 10,214.7 (3,216.3) 10,714.8 (3,155.2) 11,005.3 (3,074.6) 10,754.8 (3,264.7) 10,766.7 (2,699.9) 0.68 0.06
Dose per kg of dosing body weight 183.5 (66.7) 174.8 (59.9) 168.3 (56.1) 161.0 (59.9) 133.2 (40.2) 0.001 < 0.001










Total dose (mg) 3,549.0 (1,932.0) 3,477.8 (1,821.8) 3,787.7 (1,857.4) 3,359.8 (1,531.0) 4,256.4 (2,220.9) 0.02 0.006
Dose per kg of dosing body weight 62.1 (38.5) 56.5 (31.6) 57.2 (28.7) 49.7 (24.4) 53.5 (30.2) 0.04 0.32










Total dose (mg) 1,566.7 (457.7) 1,665.2 (597.5) 1,693.3 (700.6) 1,705.4 (796.5) 1,426.5 (584.7) 0.60 0.36
Dose per kg of dosing body weight 25.9 (9.0) 27.0 (9.9) 24.9 (10.3) 24.2 (13.1) 7.3 (54.6) 0.002 < 0.001










Total dose (mg) 173.3 (82.4) 219.9 (241.4) 256.7 (229.4) 239.4 (118.3) 262.0 (121.9) 0.18 0.01
Dose per kg of dosing body weight 3.2 (1.5) 3.6 (4.0) 3.8 (3.2) 3.3 (1.7) 3.2 (1.6) 0.63 0.96










Total dose (mg) 2,342.1 (1,179.1) 1,807.2 (791.8) 1,865.9 (990.6) 1,678.6 (920.9) 2,050.0 (916.2) 0.07 0.75













Table 4 Fluid and antibiotic dosage among different groups of BMI (Continued)










Total dose (mg) 426.8 (118.2) 489.8 (164.3) 488.0 (205.8) 441.5 (251.8) 462.5 (91.6) 0.32 0.82
Dose per kg of dosing body weight 8.0 (2.5) 8.0 (3.1) 7.1 (2.8) 6.2 (4.4) 5.3 (1.3) <
0.001
< 0.001










Total dose (mg) 1,292.5 (521.6) 1,421.2 (630.3) 1,380.4 (578.4) 1,353.1 (623.0) 1,441.4 (680.6) 0.54 0.20
Dose per kg of dosing body weight 28.5 (13.7) 22.9 (11.2) 17.9 (7.6) 14.8 (7.2) 11.3 (5.8) <
0.001
< 0.001










Total dose (mg) 682.9 (280.3) 674.4 (237.0) 671.4 (255.8) 670.3 (363.1) 682.7 (210.2) 1.0 0.13
Dose per kg of dosing body weight 13.0 (5.2) 10.9 (4.4) 10.1 (4.1) 9.1 (5.0) 7.6 (2.6) <
0.001
< 0.001










Total dose (mg) 4,106.6 (1,788.6) 4,002.3 (1,940.8) 4,326.1 (2,019.7) 4,072.1 (1,64.0) 5,071.4 (2,302.7) 0.31 0.01
Dose per kg of dosing body weight 71.8 (38.4) 64.8 (32.2) 66.5 (33.0) 61.3 (31.0) 67.0 (36.3) 0.74 0.85






Number = 2 (1.2)
Total dose (mg) 3,897.2 (4,330.8) 5,531.1 (3,998.5) 6,866.2 (5,977.6) 5,079.2 (4,933.2) 10,520.0
(10,521.7)
0.35 0.53
Dose per kg of dosing body weight 85.4 (91.9) 84.9 (59.7) 90.9 (80.2) 54.3 (52.4) 83.5 (86.7) 0.33 0.15










Total dose (mg) 2,710.0 (1,154.0) 3,547.2 (1,867.7) 2,995.3 (1,691.5) 3,025.9 (1,590.6) 3,285.7 (1,683.8) 0.08 0.10
Dose per kg of dosing body weight 47.2 (18.3) 57.5 (30.7) 46.9 (28.0) 43.9 (23.6) 42.7 (17.7) 0.01 0.48










Total dose (mg) 1,666.7 (492.4) 1,655.8 (1,052.1) 1,776.1 (884.6) 1,672.4 (943.8) 1,611.1 (607.7) 0.93 0.77
Dose per kg of dosing body weight 31.9 (10.2) 26.1 (14.4) 27.5 (12.7) 24.6 (13.7) 21.5 (8.7) 0.20 0.02










Total dose (mg) 2,578.9 (920.6) 2,171.8 (1,063.2) 2,216.9 (808.0) 2,386.4 (842.7) 2,181.8 (975.3) 0.39 0.68
Dose per kg of dosing body weight 45.3 (18.9) 35.1 (17.0) 32.7 (12.9) 34.6 (15.0) 26.7 (12.1) 0.01 0.02
aCrystalloid, colloid, crystalloid equivalent volume, red blood cell and fresh frozen plasma for first six hours. All others for day 1. bAdjusted for creatinine clearance. cAdjusted for creatinine clearance and pulmonary














Crude hospital mortality, ICU mortality, hospital LOS
and ICU LOS differed among the BMI groups (Table 5).
Compared with patients with normal BMI, the crude
OR for obese patients was 0.80, 95% CI 0.66 to 0.97 and
for the morbidly obese was 0.61, 95% CI 0.44 to 0.85.
After adjustment for baseline characteristics (model 1)
and for baseline characteristics and sepsis interventions
(model 2), the OR and CI became non-significant statis-
tically (Figure 1).
Discussion
Our study found that: 1) the BMI of patients with septic
shock varies considerably; 2) septic shock in the obese
and very obese differs in the presentation, sites of infec-
tion and microbiology compared to non-obese patients;
3) sepsis interventions, especially the volume of resusci-
tation fluids and doses of antibiotics, do not appear to
take into consideration the variations in BMI, leading to
considerable differences in weight-adjusted doses; and 4)
crude hospital mortality of obese and morbidly obese
patients with septic shock was lower than normal weight
patients, but this was explained at least in part by differ-
ences in baseline characteristics and sepsis interventions.
Our study revealed that obese and morbidly patients
with septic shock display some differences in their clini-
cal presentation, site and type of infection. Indeed,
underweight and very obese patients with septic shock
had fewer hemodynamic disturbances and, thus, required
lower doses of vasopressors (expressed as mcg/kg/minute
for norepinephrine and epinephrine) than normal weight
patients, although with comparable APACHE II scores.
Further, the source of infection in obese patients was
more likely to be related to skin and soft tissue infections
and less likely to be related to pneumonia with predomi-
nantly Gram-positive microorganisms.
Our study examined the influence of weight and BMI
on sepsis interventions. We observed that similar
volumes of resuscitation fluids and similar total doses of
antimicrobials were administered regardless of BMI. This
translated to lower volume/kg and dose/kg in the obese
and very obese patients compared to the normal BMI
patients even after adjustment for wedge pressure and
creatinine clearance. For example, we found that very
obese patients received 27.7 ± 22.0 ml/kg crystalloid












Hospital mortality, number (%) 121 (61.7) 580 (56.9) 444 (54.4) 349 (51.3) 76 (44.7) 0.003
ICU mortality, number (%) 102 (52.0) 451 (44.2) 335 (41.1) 265 (39.0) 57 (33.5) 0.001
ICU length of stay, mean (SD) 9.9 (9.4) 10.5 (12.5) 11.4 (14.7) 11.2 (14.3) 12.2 (12.7) 0.30
Hospital length of stay, mean (SD) 25.1 (33.6) 25.1 (31.8) 27.8 (35.2) 26.5 (34.8) 34.3 (44.2) 0.02
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Figure 1 Odds ratios and confidence intervals of hospital mortality among different BMI groups in multivariate logistic regression
analysis. Panel A: Crude analysis. Panel B: Adjusted analysis to baseline characteristics (model 1). Panel C: Adjusted analysis to baseline
characteristics and sepsis interventions (model 2). BMI, body mass index.
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volume in the first six hours compared to 55.0 ± 40.1 ml/
kg in the underweight group. This probably reflects rou-
tine clinical practice which is not weight-based as physi-
cians often administer a standard bolus of 1,000 ml
crystalloid or 300 to 500 ml colloid, irrespective of body
weight. Unlike pediatricians, physicians caring for adult
patients do not routinely take weight and height into
consideration in decision-making. The issue is further
confounded by the large number of correction formulae
for weight adjustment (actual, adjusted, ideal, predicted,
antimicrobial dosing body weights) that are mostly not
based on clinical outcome studies, leaving the bedside
practitioner unclear about the best approach [6,29].
Additionally, it remains unclear whether dosing vasopres-
sors, such as norepinephrine and epinephrine, based on
weight (as mcg/kg/minute) is superior to non-weight
based dosing (as mcg/minute) as both approaches are
seen in practice and in clinical trials [30,31].
Our study shows that crude hospital mortality of obese
and very obese patients with septic shock was lower than
normal weight patients. Because the effect became insig-
nificant after adjustment, we believe that the observed dif-
ferences in mortality were explained partially by baseline
characteristics and sepsis interventions. The effect of obe-
sity on outcome of critically ill patients has been a subject
of considerable debate [32]. Two meta-analyses revealed
discordant results, with one showing no difference in mor-
tality between obese and normal-weight critically ill adults
[33] and another demonstrating a trend toward decreased
risk of mortality in overweight and obese patients com-
pared with those with normal BMI [11]. In septic shock, a
retrospective study of 301 patients with septic shock found
that overweight and obese patients had lower mortality
than those with normal weight [18].
Despite this supportive evidence, how a condition that
increases cause-specific mortality, such as ischemic heart
disease, diabetes, cancer and respiratory diseases, can be
neutral or even provides a survival advantage during criti-
cal illness, remains perplexing. Several possible explana-
tions exist. First, epidemiologic and statistical reasons may
explain the association. The lower observed mortality
might be related to lead-time bias and to the earlier age in
the very obese septic patients. Additionally, the obese and
morbidly obese patients may be ‘healthier’ than the normal
BMI patients. Obese patients displayed more diabetes and
related complications, while the normal weight had more
devastating illnesses, including hematologic and solid
organ malignancies. Therefore, the observed differences in
outcome may be related to worse outcome in the normal
weight patients and not to ‘better’ outcome in the obese.
Additionally, septic shock in the obese and very obese may
be less severe as shown by the lower vasopressor doses.
The calibration of APACHE II in morbidly obese patients
has to be validated, because several of its components,
such as oxygenation, may be altered due to obesity and
not to the acute illness. Finally, although we adjusted for
several co-morbidities, residual confounding cannot be
ruled out.
Second, our study identified differences in sepsis inter-
ventions as one of the potential explanations for this
apparent paradox. Several studies have highlighted dispari-
ties in care provided to patients in the obese and very
obese groups compared with patients in other categories
[34,35]. At present, there is no strong evidence to support
whether a weight-based approach for fluid resuscitation,
antibiotic or vasopressor dosing is superior to the non-
weight-based approach. Our study shows clearly that
obese patients received a lower amount of resuscitation
fluids and dose of antibiotics based on weight. Although
one cannot establish a causal relationship with mortality,
emerging evidence suggests that over-resuscitation may
have detrimental effects [36,37]. Therefore, it is appealing
to speculate that this may have contributed to the higher
mortality in both lower and normal BMI patients, thus
making obesity appear neutral or protective. Further, our
study did not examine other important sepsis interven-
tions, such as tidal volume [38,39] and doses of other
medications, all of which deserve further study.
Third, the observed association of obesity with lower
mortality may be related to true biological reasons. One
explanation is an underlying difference in metabolic and
immune response to acute illness [40]. Obesity activates
many inflammatory pathways that deregulate physiological
responses, which maintain metabolic homeostasis includ-
ing insulin and leptin sensitivity. One can speculate that a
superimposed episode of acute inflammation triggered by
sepsis on top of the chronic inflammation may induce a
different immune response than in naïve patients. A sec-
ond possible explanation has been variations in vital signs
leading to perception of higher severity of illness [8]. How-
ever, in our cohort of patients with septic shock, we found
that very obese patients had a slightly lower heart rate and
respiratory rate and higher blood pressure and tempera-
ture, which may be related to a different response but
could also be simply related to less severe shock in con-
trast to what has been suggested by Martino et al. [8].
It is important to note that these findings apply to the
individual episode of septic shock only. Once septic shock
sets in, our data suggest that patients in the obese and
very obese groups may have outcomes that are similar or
not worse than those in other groups. We did not capture
data about the association between obesity and predisposi-
tion to sepsis in the general population. However, consid-
ering the younger age of very obese patients in the septic
population, one may question whether obesity actually
increases the risk for septic shock. This point and the life-
long consequences of septic shock on the obese patients
need to be studied in a population-based cohort.
Arabi et al. Critical Care 2013, 17:R72
http://ccforum.com/content/17/2/R72
Page 10 of 13
Our study should be interpreted in light of its
strengths and limitations. To our knowledge, this is the
largest study to date specifically addressing the impact
of obesity on outcomes among patients with septic
shock. The inclusion of patients from 28 ICUs based in
three geographic regions lends the study wide generaliz-
ability. In terms of limitations, the findings only high-
light associations and cause-effect relationships cannot
be inferred. We used the weight and height as docu-
mented in the medical records, the precision of which
could not be verified. The availability of BMI data on
only one third of patients may have led to selection bias.
However, the comparison between excluded and
included patients showed minor differences that are
unlikely to explain the magnitude of the observed differ-
ences among BMI groups. Furthermore, this lack of data
may represent perception bias as healthcare workers are
more likely to measure height and weight in extreme
groups of BMI. Our study did not address the possibility
of measurement bias arising from systematic errors in
measuring weight, height and blood pressure across dif-
ferent BMI groups. We adjusted for severity of illness as
measured by APACHE II and other possible confoun-
ders; we cannot rule out residual confounding especially
considering the large number of possible factors that
may influence outcome in acutely ill patients. Finally, we
do not have data on the sagittal abdominal diameter,
which has been shown to be an independent risk factor
of death in critically ill patients [41].
Conclusions
In the septic shock population, we observed the obesity
paradox (lower mortality in the obese) reported in other
populations. This may be related in part to differences
in patient characteristics. However, the true paradox
may lie in the variations in the sepsis interventions,
such as the administration of resuscitation fluids and
antimicrobial therapy. Further studies are warranted to
examine whether a weight-based approach to common
therapeutic interventions in septic shock influences
outcome.
Key messages
• The presentation, microbiology and organ failures
are different among obese patients compared to the
non-obese.
• Very obese patients presented at an early age to
the ICU with septic shock and had more underlying
chronic co-morbidities compared to non-obese
patients.
• There is a considerable variation in the volume of
fluid resuscitation per kg and antibiotic dosing
among different BMI groups.
• The obesity paradox (lower mortality in the obese)
as reported in other populations was observed in
septic shock patients as well.
• The true paradox may lie in the variations in the
sepsis interventions, such as the administration of
resuscitation fluids.
Additional material
Additional file 1: Appendix A: Definitions of organ failures. Appendix
B: Formulas.
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